Southeast Asset Advisors LLC Trims Stake in Pfizer Inc. (NYSE:PFE)

Southeast Asset Advisors LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 4.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,746 shares of the biopharmaceutical company’s stock after selling 2,035 shares during the period. Southeast Asset Advisors LLC’s holdings in Pfizer were worth $1,187,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. United Bank grew its stake in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 1,277 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Pfizer by 0.5% during the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock worth $15,348,000 after acquiring an additional 2,600 shares during the last quarter. Kovitz Investment Group Partners LLC grew its position in Pfizer by 35.4% in the third quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock worth $10,612,000 after acquiring an additional 95,896 shares in the last quarter. DF Dent & Co. Inc. increased its stake in Pfizer by 11.9% in the third quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock valued at $1,323,000 after acquiring an additional 4,852 shares during the last quarter. Finally, Dunhill Financial LLC raised its position in Pfizer by 8,848.4% during the third quarter. Dunhill Financial LLC now owns 105,323 shares of the biopharmaceutical company’s stock valued at $3,048,000 after purchasing an additional 104,146 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $22.99 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $130.39 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1-year low of $22.28 and a 1-year high of $31.54. The firm has a 50-day moving average of $25.87 and a 200-day moving average of $26.72.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on PFE shares. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.